Modeling the human skin barrier - Towards a better understanding of dermal absorption

Advanced Drug Delivery Reviews

Volumn 65, Issue 2, 2013, Pages 152-168

  Jepps, Owen G ^a   Dancik, Yuri ^d   Anissimov, Yuri G ^a   Roberts, Michael S ^b,c  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d Proctor and Gamble Eurocor   (Belgium)

Author keywords

Barrier; Dermal absorption; Distribution; Human skin; Modeling; Transdermal drug transport; Transdermal penetration

Indexed keywords

BARRIER; DERMAL ABSORPTION; DISTRIBUTION; HUMAN SKIN; TRANSDERMAL; TRANSDERMAL DRUGS;

MEDICINE; MODELS;

DRUG DELIVERY;

ANTIHISTAMINIC AGENT; CORTICOSTERONE; DICLOFENAC; FENTANYL; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; LIDOCAINE; LIPOSOME; MANNITOL; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NOREPHEDRINE; PHENYLEPHRINE; RETINOID; SALICYLIC ACID;

ANTIINFLAMMATORY ACTIVITY; CELL STRUCTURE; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; EPIDERMIS; HAIR FOLLICLE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MATHEMATICAL MODEL; PARTITION COEFFICIENT; PRIORITY JOURNAL; REVIEW; SKIN; SKIN ABSORPTION; SKIN BARRIER; STEADY STATE; STRATUM CORNEUM; TRANSDERMAL DRUG ADMINISTRATION; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION; TISSUE DISTRIBUTION;

EID: 84873523117     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.04.003     Document Type: Review

References (175)

1. Cross S.E., Roberts M.S. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development?. Curr. Drug Deliv. 2004, 1:81-92.
2. Joshi A., Raje J. Sonicated transdermal drug transport. J. Control. Release 2002, 83:13-22.
3. Roberts M.S., Cross S.E., Pellett M.A. Skin transport. Dermatological and Transdermal Formulations 2002, Marcel Dekker, New York. K.A. Walters (Ed.).
4. Schaefer H., Redelmeier T.E., Lademann J. Skin penetration. Contact Dermatitis 2011, 215-227. Springer-Verlag, Berlin. J.D. Johansen, P.J. Frosch, J.-P. Lepoittevin (Eds.).
5. Schneider M., Stracke F., Hansen S., Schaefer U.F. Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinol 2009, 1:197-206.
6. Contri R.V., Fiel L.A., Pohlmann A.R., Guterres S.S., Beck R.C.R. Transport of substances and nanoparticles across the skin and in vitro models to evaluate skin permeation and/or penetration. Nanocosmetics and Nanomedicines: New Approaches for Skin Care 2011, 3-36. Springer-Verlag, Berlin. R.C.R. Beck, S.S. Guterres, A.R. Pohlmann (Eds.).
7. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 2001, 14:101-114.
8. Hadgraft J. Skin, the final frontier. Int. J. Pharm. 2001, 224:1-18.
9. Anissimov Y.G., Jepps O.G., Dancik Y., Roberts M.S. Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes. Adv. Drug Del. Rev. 2013, 65:169-190.
10. Samuelsson K., Simonsson C., Jonsson C.A., Westman G., Ericson M.B., Karlberg A.T. Accumulation of FITC near stratum corneum-visualizing epidermal distribution of a strong sensitizer using two-photon microscopy. Contact Dermatitis 2009, 61:91-100.
11. Konig K., Raphael A.P., Lin L., Grice J.E., Soyer H.P., Breunig H.G., Roberts M.S., Prow T.W. Applications of multiphoton tomographs and femtosecond laser nanoprocessing microscopes in drug delivery research. Adv. Drug Deliv. Rev. 2011, 63:388-404.
12. Roberts M.S., Dancik Y., Prow T.W., Thorling C.A., Lin L.L., Grice J.E., Robertson T.A., Konig K., Becker W. Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. Eur. J. Pharm. Biopharm. 2011, 77:469-488.
13. Scheuplein R.J., Blank I.H. Permeability of the skin. Physiol. Rev. 1971, 51:702-747.
14. Walters K.A., Roberts M.S. The structure and function of skin. Dermatological and Transdermal Formulations 2002, 1-41. Marcel Dekker, New York. K.A. Walters (Ed.).
15. Bouwstra J.A., Thewalt J., Gooris G.S., Kitson N. A model membrane approach to the epidermal permeability barrier: an X-ray diffraction study. Biochemistry 1997, 36:7717-7725.
16. Norlen L. The physical structure of the skin barrier. Dermal Absorption and Toxicity Assessment 2008, 37-68. Informa Healthcare, New York. M.S. Roberts, K.A. Walters (Eds.).
17. Elias P.M. Epidermal lipids, barrier function, and desquamation. J. Invest. Dermatol. 1983, 80:44s-49s.
18. Madison K.C. Barrier function of the skin: "la raison d'etre" of the epidermis. J. Invest. Dermatol. 2003, 121:231-241.
19. McGrath J.A., Eady R.A.J., Pope F.M. Anatomy and Organization of Human Skin, Rook's Textbook of Dermatology 2004.
20. Michaels A.C., Chandrasekaran S.K., Shaw J.E. Drug permeation through human skin: theory and in vitro experimental measurement. AICHE J. 1975, 21:985-996.
21. Bouwstra J.A., de Graaff A., Gooris G.S., Nijsse J., Wiechers J.W., van Aelst A.C. Water distribution and related morphology in human stratum corneum at different hydration levels. J. Invest. Dermatol. 2003, 120:750-758.
22. Yotsuyanagi T., Higuchi W.I. A two phase series model for the transport of steroids across the fully hydrated stratum corneum. J. Pharm. Pharmacol. 1972, 24:934-941.
23. Squier C.A. The permeability of keratinized and nonkeratinized oral epithelium to horseradish peroxidase. J. Ultrastruct. Res. 1973, 43:160-177.
24. Elias P.M., Friend D.S. The permeability barrier in mammalian epidermis. J. Cell Biol. 1975, 65:180-191.
25. Albery W.J., Hadgraft J. Percutaneous absorption: theoretical description. J. Pharm. Pharmacol. 1979, 31:129-139.
26. Bodde H.E., van den Brink I., Koerten H.K., de Haan F.H.N. Visualization of in vitro percutaneous penetration of mercuric chloride; transport through intercellular space versus cellular uptake through desmosomes. J. Control. Release 1997, 15:227-236.
27. Siddiqui O., Roberts M.S., Polack A.E. Percutaneous absorption of steroids: relative contributions of epidermal penetration and dermal clearance. J. Pharmacokinet. Biopharm. 1989, 17:405-424.
28. Scheuplein R.J. Mechanism of percutaneous adsorption. I. Routes of penetration and the influence of solubility. J. Invest. Dermatol. 1965, 45:334-346.
29. Roberts M.S., Anderson R.A., Swarbrick J. Permeability of human epidermis to phenolic compounds. J. Pharm. Pharmacol. 1977, 29:677-683.
30. Peck K.D., Ghanem A.H., Higuchi W.I. Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm. Res. 1994, 11:1306-1314.
31. Crank J. The Mathematics of Diffusion 1975, Clarendon Press, Oxford, UK.
32. Anissimov Y.G., Roberts M.S. Diffusion modeling of percutaneous absorption kinetics. 1. Effects of flow rate, receptor sampling rate, and viable epidermal resistance for a constant donor concentration. J. Pharm. Sci. 1999, 88:1201-1209.
33. Anissimov Y.G., Roberts M.S. Diffusion modeling of percutaneous absorption kinetics: 3. Variable diffusion and partition coefficients, consequences for stratum corneum depth profiles and desorption kinetics. J. Pharm. Sci. 2004, 93:470-487.
34. Anissimov Y.G., Roberts M.S. Diffusion modelling of percutaneous absorption kinetics: 4. Effects of a slow equilibration process within stratum corneum on absorption and desorption kinetics. J. Pharm. Sci. 2009, 98:772-781.
35. Anissimov Y.G. Mathematical models for different exposure conditions. Dermal Absorption and Toxicity Assessment 2008, 271-286. Informa Healthcare, New York. M.S. Roberts, K.A. Walters (Eds.).
36. Frasch H.F., Barbero A.M. Steady-state flux and lag time in the stratum corneum lipid pathway: results from finite element models. J. Pharm. Sci. 2003, 92:2196-2207.
37. Barbero A.M., Frasch H.F. Transcellular route of diffusion through stratum corneum: results from finite element models. J. Pharm. Sci. 2006, 95:2186-2194.
38. Wang T.F., Kasting G.B., Nitsche J.M. A multiphase microscopic diffusion model for stratum corneum permeability. II. Estimation of physicochemical parameters, and application to a large permeability database. J. Pharm. Sci. 2007, 96:3024-3051.
39. Raykar P.V., Fung M.C., Anderson B.D. The role of protein and lipid domains in the uptake of solutes by human stratum corneum. Pharm. Res. 1988, 5:140-150.
40. Nitsche J.M., Wang T.F., Kasting G.B. A two-phase analysis of solute partitioning into the stratum corneum. J. Pharm. Sci. 2006, 95:649-666.
41. Roberts M.S., Cross S.E., Anissimov Y.G. The skin reservoir for topically applied solutes. Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methodology 2005, 213-234. Taylor & Francis, Boca Raton. R.L. Bronaugh, H.I. Maibach (Eds.).
42. Ritschel W.A., Hussain A.S. The principles of permeation of substances across the skin. Methods Find. Exp. Clin. Pharmacol. 1988, 10:39-56.
43. Jakubovic H.R., Ackerman A.B. Structure and function of skin: development, morphology, and physiology. Dermatology 1992, 3-87. W.B. Saunders, Philadelphia. S.L. Moschella, H.J. Hurley (Eds.).
44. Wenkers B.P., Lippold B.C. Skin penetration of nonsteroidal antiinflammatory drugs out of a lipophilic vehicle: influence of the viable epidermis. J. Pharm. Sci. 1999, 88:1326-1331.
45. Bhatt V.D., Soman R.S., Miller M.A., Kasting G.B. Permeation of tecnazene through human skin in vitro as assessed by HS-SPME and GC-MS. Environ. Sci. Technol. 2008, 42:6587-6592.
46. Liu P., Higuchi W.I., Song W.Q., Kurihara-Bergstrom T., Good W.R. Quantitative evaluation of ethanol effects on diffusion and metabolism of beta-estradiol in hairless mouse skin. Pharm. Res. 1991, 8:865-872.
47. Hikima T., Yamada K., Kimura T., Maibach H.I., Tojo K. Comparison of skin distribution of hydrolytic activity for bioconversion of beta-estradiol 17-acetate between man and several animals in vitro. Eur. J. Pharm. Biopharm. 2002, 54:155-160.
48. Heard C.M., Monk B.V., Modley A.J. Binding of primaquine to epidermal membranes and keratin. Int. J. Pharm. 2003, 257:237-244.
49. Bleasby K., Castle J.C., Roberts C.J., Cheng C., Bailey W.J., Sina J.F., Kulkarni A.V., Hafey M.J., Evers R., Johnson J.M., Ulrich R.G., Slatter J.G. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006, 36:963-988.
50. Flynn G.L., Yalkowsky S.H. Correlation and prediction of mass transport across membranes. I. Influence of alkyl chain length on flux-determining properties of barrier and diffusant. J. Pharm. Sci. 1972, 61:838-852.
51. Roberts M.S., Anderson R.A., Swarbrick J., Moore D.E. The percutaneous absorption of phenolic compounds: the mechanism of diffusion across the stratum corneum. J. Pharm. Pharmacol. 1978, 30:486-490.
52. Cleek R.L., Bunge A.L. A new method for estimating dermal absorption from chemical exposure. 1. General approach. Pharm. Res. 1993, 10:497-506.
53. Bunge A.L., Cleek R.L., Vecchia B.E. A new method for estimating dermal absorption from chemical exposure. 3. Compared with steady-state methods for prediction and data analysis. Pharm. Res. 1995, 12:972-982.
54. Gregoire S., Ribaud C., Benech F., Meunier J.R., Garrigues-Mazert A., Guy R.H. Prediction of chemical absorption into and through the skin from cosmetic and dermatological formulations. Br. J. Dermatol. 2009, 160:80-91.
55. Reddy M.B., Guy R.H., Bunge A.L. Does epidermal turnover reduce percutaneous penetration?. Pharm. Res. 2000, 17:1414-1419.
56. Simon L., Goyal A. Dynamics and control of percutaneous drug absorption in the presence of epidermal turnover. J. Pharm. Sci. 2009, 98:187-204.
57. Khalil E., Kretsos K., Kasting G.B. Glucose partition coefficient and diffusivity in the lower skin layers. Pharm. Res. 2006, 23:1227-1234.
58. Walter K., Kurz H. Binding of drugs to human skin: influencing factors and the role of tissue lipids. J. Pharm. Pharmacol. 1988, 40:689-693.
59. Yagi S., Nakayama K., Kurosaki Y., Higaki K., Kimura T. Factors determining drug residence in skin during transdermal absorption: studies on beta-blocking agents. Biol. Pharm. Bull. 1998, 21:1195-1201.
60. Ibrahim R., Kasting G.B. Improved method for determining partition and diffusion coefficients in human dermis. J. Pharm. Sci. 2010, 99:4928-4939.
61. Cross S.E., Magnusson B.M., Winckle G., Anissimov Y., Roberts M.S. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. J. Invest. Dermatol. 2003, 120:759-764.
62. Magnusson B.M., Cross S.E., Winckle G., Roberts M.S. Percutaneous absorption of steroids: determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol. Physiol. 2006, 19:336-342.
63. Sugibayashi K., Hayashi T., Morimoto Y. Simultaneous transport and metabolism of ethyl nicotinate in hairless rat skin after its topical application: the effect of enzyme distribution in skin. J. Control. Release 1999, 62:201-208.
64. Boderke P., Schittkowski K., Wolf M., Merkle H.P. Modeling of diffusion and concurrent metabolism in cutaneous tissue. J. Theor. Biol. 2000, 204:393-407.
65. Li Q., Tsuji H., Kato Y., Sai Y., Kubo Y., Tsuji A. Characterization of the transdermal transport of flurbiprofen and indomethacin. J. Control. Release 2006, 110:542-556.
66. Grams Y.Y., Bouwstra J.A. Penetration and distribution in human skin focusing on the hair follicle. Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methods 2005, Taylor & Francis, Boca Raton. R.L. Bronaugh, H.I. Maibach (Eds.).
67. Braverman I.M., Keh A., Goldminz D. Correlation of laser Doppler wave patterns with underlying microvascular anatomy. J. Invest. Dermatol. 1990, 95:283-286.
68. Braverman I.M. The cutaneous microcirculation. J. Investig. Dermatol. Symp. Proc. 2000, 5:3-9.
69. Cevc G., Vierl U. Spatial distribution of cutaneous microvasculature and local drug clearance after drug application on the skin. J. Control. Release 2007, 118:18-26.
70. O'Driscoll C.M. Anatomy and physiology of the lymphatics. Lymphatics Transport of Drugs 1992, CRC Press, Boca Raton. W.N. Charman, V.J. Stella (Eds.).
71. Riviere J.E., Sage B., Williams P.L. Effects of vasoactive drugs on transdermal lidocaine iontophoresis. J. Pharm. Sci. 1991, 80:615-620.
72. Riviere J.E., Monteiro-Riviere N.A., Inman A.O. Determination of lidocaine concentrations in skin after transdermal iontophoresis: effects of vasoactive drugs. Pharm. Res. 1992, 9:211-214.
73. Singh P., Roberts M.S. Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds. J. Pharm. Sci. 1994, 83:783-791.
74. Borg N., Gotharson E., Benfeldt E., Groth L., Stahle L. Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis. Acta Derm. Venereol. 1999, 79:274-277.
75. Cross S.E., Megwa S.A., Benson H.A., Roberts M.S. Self promotion of deep tissue penetration and distribution of methylsalicylate after topical application. Pharm. Res. 1999, 16:427-433.
76. Sugibayashi K., Yanagimoto G., Hayashi T., Seki T., Juni K., Morimoto Y. Analysis of skin disposition of flurbiprofen after topical application in hairless rats. J. Control. Release 1999, 62:193-200.
77. Boutsiouki P., Thompson J.P., Clough G.F. Effects of local blood flow on the percutaneous absorption of the organophosphorus compound malathion: a microdialysis study in man. Arch. Toxicol. 2001, 75:321-328.
78. Clough G.F., Boutsiouki P., Church M.K., Michel C.C. Effects of blood flow on the in vivo recovery of a small diffusible molecule by microdialysis in human skin. J. Pharmacol. Exp. Ther. 2002, 302:681-686.
79. Higaki K., Asai M., Suyama T., Nakayama K., Ogawara K., Kimura T. Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. Int. J. Pharm. 2002, 239:129-141.
80. Morgan C.J., Renwick A.G., Friedmann P.S. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. Br. J. Dermatol. 2003, 148:434-443.
81. Higaki K., Nakayama K., Suyama T., Amnuaikit C., Ogawara K., Kimura T. Enhancement of topical delivery of drugs via direct penetration by reducing blood flow rate in skin. Int. J. Pharm. 2005, 288:227-233.
82. Cross S.E., Roberts M.S. Targeting local tissues by transdermal application: understanding drug physicochemical properties that best exploit protein binding and blood flow effects. Drug Dev. Res. 1999, 46:309-315.
83. McNeill S.C., Potts R.O., Francoeur M.L. Local enhanced topical delivery (LETD) of drugs: does it truly exist?. Pharm. Res. 1992, 9:1422-1427.
84. Monteiro-Riviere N.A., Inman A.O., Riviere J.E., McNeill S.C., Francoeur M.L. Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature. Pharm. Res. 1993, 10:1326-1331.
85. Cross S.E., Wu Z., Roberts M.S. The effect of protein binding on the deep tissue penetration and efflux of dermally applied salicylic acid, lidocaine and diazepam in the perfused rat hindlimb. J. Pharmacol. Exp. Ther. 1996, 277:366-374.
86. Bocci V., Pessina G.P., Paulesu L., Nicoletti C. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph. J. Biol. Response Mod. 1988, 7:390-400.
87. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 1990, 7:167-169.
88. Yoshikawa H., Takada K., Muranishi S. Molecular weight-dependent lymphatic transfer of exogenous macromolecules from large intestine of renal insufficiency rats. Pharm. Res. 1992, 9:1195-1198.
89. Cross S.E., Roberts M.S. Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. J. Pharm. Pharmacol. 1993, 45:606-609.
90. Cross S.E., Roberts M.S. Dermal blood flow, lymphatics, and binding as determinants of topical absorption, clearance, and distribution. Dermal Absorption Models in Toxicology and Pharmacology 2006, Taylor & Francis, Boca Raton. J.E. Riviere (Ed.).
91. Schmuth M., Ortegon A.M., Mao-Qiang M., Elias P.M., Feingold K.R., Stahl A. Differential expression of fatty acid transport proteins in epidermis and skin appendages. J. Invest. Dermatol. 2005, 125:1174-1181.
92. Skazik C., Wenzel J., Marquardt Y., Kim A., Merk H.F., Bickers D.R., Baron J.M. P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. Exp. Dermatol. 2011, 20:450-452.
93. Ito K., Nguyen H.T., Kato Y., Wakayama T., Kubo Y., Iseki S., Tsuji A. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin. J. Control. Release 2008, 131:198-204.
94. Ito K., Kato Y., Tsuji H., Nguyen H.T., Kubo Y., Tsuji A. Involvement of organic anion transport system in transdermal absorption of flurbiprofen. J. Control. Release 2007, 124:60-68.
95. Roberts M.S., Cross S.E. A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. Pharm. Res. 1999, 16:1392-1398.
96. Singh P., Roberts M.S. Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application. J. Pharmacokinet. Biopharm. 1993, 21:337-373.
97. Singh P., Maibach H.I., Roberts M.S. Site of effects. Dermal Absorption and Toxicity Assessment 1998, 353-370. Marcel Dekker, New York. M.S. Roberts, K.A. Walters (Eds.).
98. Dancik Y., Anissimov Y.G., Jepps O.G., Roberts M.S. Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. Br J Clin Dermatol 2012, 73:841-855.
99. Anissimov Y.G., Roberts M.S. Modelling dermal drug distribution after topical application in human. Pharm. Res. 2011, 28:2119-2129.
100. Roberts M.S., Rowland M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 1986, 14:227-260.
101. Anissimov Y.G., Bracken A.J., Roberts M.S. Interconnected-tubes model of hepatic elimination. J. Theor. Biol. 1997, 188:89-101.
102. Kretsos K., Kasting G.B., Nitsche J.M. Distributed diffusion-clearance model for transient drug distribution within the skin. J. Pharm. Sci. 2004, 93:2820-2835.
103. Kretsos K., Miller M.A., Zamora-Estrada G., Kasting G.B. Partitioning, diffusivity and clearance of skin permeants in mammalian dermis. Int. J. Pharm. 2008, 346:64-79.
104. Dancik Y., Miller M.A., Jaworska J., Kasting G.B. Design and performance of a spreadsheet-based model for estimating bioavailability of chemicals from dermal exposure. Adv. Drug Del. Rev. 2013, 65:221-236.
105. Peyret T., Poulin P., Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol. Appl. Pharmacol. 2010, 249:197-207.
106. Weiss H.M., Fresneau M., Moenius T., Stuetz A., Billich A. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab. Dispos. 2008, 36:1812-1818.
107. Lee C.M., Maibach H.I. Deep percutaneous penetration into muscles and joints. J. Pharm. Sci. 2006, 95:1405-1413.
108. Agarwal R., Katare O.P., Vyas S.P. The pilosebaceous unit: a pivotal route for topical drug delivery. Methods Find. Exp. Clin. Pharmacol. 2000, 22:129-133.
109. Valiveti S., Wesley J., Lu G.W. Investigation of drug partition property in artificial sebum. Int. J. Pharm. 2008, 346:10-16.
110. Zouboulis C.C. Sebaceous gland in human skin-the fantastic future of a skin appendage. J. Invest. Dermatol. 2003, 120:xiv-xv.
111. Meidan V.M., Bonner M.C., Michniak B.B. Transfollicular drug delivery-is it a reality?. Int. J. Pharm. 2005, 306:1-14.
112. Schaefer H., Lademann J. The role of follicular penetration. A differential view. Skin Pharmacol. Appl. Skin Physiol. 2001, 14(Suppl. 1):23-27.
113. Odland G.F. Structure of the skin. Physiology, Morphology and Molecular Biology of the Skin 1991, 110. Oxford University Press, New York. L.A. Goldsmith (Ed.).
114. Lauer A.C. Percutaneous drug delivery to the hair follicle. Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methods 2005, Taylor & Francis, Boca Raton. R.L. Bronaugh, H.I. Maibach (Eds.).
115. Ellis R.A. Vascular patterns in the skin. Advances in Biology of the Skin 1961, 20-36. Pergamon Press, New York. W. Montagna, R.A. Ellis (Eds.).
116. Montagna W., Kligman A.M., Carslile K.S. Atlas of Normal Human Skin 1992, Springer-Verlag, New York.
117. Cross S.E., Anderson C., Roberts M.S. Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br. J. Clin. Pharmacol. 1998, 46:29-35.
118. Sato K., Leidal R., Sato F. Morphology and development of an apoeccrine sweat gland in human axillae. Am. J. Physiol. 1987, 252:R166-R180.
119. Wilke K., Wepf R., Keil F.J., Wittern K.P., Wenck H., Biel S.S. Are sweat glands an alternate penetration pathway? Understanding the morphological complexity of the axillary sweat gland apparatus. Skin Pharmacol. Physiol. 2006, 19:38-49.
120. Hurley H.J. The eccrine sweat glands: structure and function. The Biology of the Skin 2001, 47-76. Parthenon, New York. R.K. Freinkel, D.T. Woodley (Eds.).
121. Scheuplein R.J. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J. Invest. Dermatol. 1967, 48:79-88.
122. Grams Y.Y., Whitehead L., Cornwell P., Bouwstra J.A. Time and depth resolved visualisation of the diffusion of a lipophilic dye into the hair follicle of fresh unfixed human scalp skin. J. Control. Release 2004, 98:367-378.
123. Grams Y.Y., Whitehead L., Cornwell P., Bouwstra J.A. On-line visualization of dye diffusion in fresh unfixed human skin. Pharm. Res. 2004, 21:851-859.
124. Lauer A.C., Elder J.T., Weiner N.D. Evaluation of the hairless rat as a model for in vivo percutaneous absorption. J. Pharm. Sci. 1997, 86:13-18.
125. Wu H., Ramachandran C., Weiner N.D., Roessler B.J. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int. J. Pharm. 2001, 220:63-75.
126. Bernard E., Dubois J.L., Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of liposomes. J. Pharm. Sci. 1997, 86:573-578.
127. Jacobi U., Kaiser M., Sterry W., Lademann J. Kinetics of blood flow after topical application of benzyl nicotinate on different anatomic sites. Arch. Dermatol. Res. 2006, 298:291-300.
128. Ogiso T., Shiraki T., Okajima K., Tanino T., Iwaki M., Wada T. Transfollicular drug delivery: penetration of drugs through human scalp skin and comparison of penetration between scalp and abdominal skins in vitro. J. Drug Target. 2002, 10:369-378.
129. Lieb L.M., Liimatta A.P., Bryan R.N., Brown B.D., Krueger G.G. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. J. Pharm. Sci. 1997, 86:1022-1029.
130. Lademann J., Richter H., Schaefer U.F., Blume-Peytavi U., Teichmann A., Otberg N., Sterry W. Hair follicles-a long-term reservoir for drug delivery. Skin Pharmacol. Physiol. 2006, 19:232-236.
131. Cone E.J. Mechanisms of drug incorporation into hair. Ther. Drug Monit. 1996, 18:438-443.
132. Kelch A., Wessel S., Will T., Hintze U., Wepf R., Wiesendanger R. Penetration pathways of fluorescent dyes in human hair fibres investigated by scanning near-field optical microscopy. J. Microsc. 2000, 200:179-186.
133. Johnson H.L., Maibach H.I. Drug excretion in human eccrine sweat. J. Invest. Dermatol. 1971, 56:182-188.
134. Jackson R.J., Davis W.B. A mathematical approach to the prediction of the rate of penetration of ions in the sweat duct. J. Theor. Biol. 1982, 97:481-489.
135. Lademann J., Richter H., Otberg N., Lawrenz F., Blume-Peytavi U., Sterry W. Application of a dermatological laser scanning confocal microscope for investigation in skin physiology. Laser Phys. 2003, 13:756-760.
136. Lademann J., Otberg N., Richter H., Meyer L., Audring H., Teichmann A., Thomas S., Knuttel A., Sterry W. Application of optical non-invasive methods in skin physiology: a comparison of laser scanning microscopy and optical coherent tomography with histological analysis. Skin Res. Technol. 2007, 13:119-132.
137. Jacobi U., Waibler E., Schulze P., Sehouli J., Oskay-Ozcelik G., Schmook T., Sterry W., Lademann J. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann. Oncol. 2005, 16:1210-1211.
138. Schmook T., Jacobi U., Lademann J., Worm M., Stockfleth E. Detection of doxorubicin in the horny layer in a patient suffering from palmar-plantar erythrodysaesthesia. Dermatology 2005, 210:237-238.
139. Zelickson A.S. Electron microscopic study of epidermal sweat duct. Arch. Dermatol. 1961, 83:106-111.
140. Hashimoto K., Gross B.G., Lever W.F. The ultrastructure of the skin of human embryos. I. The intraepidermal eccrine sweat duct. J. Invest. Dermatol. 1965, 45:139-151.
141. Dancik Y., Jepps O.G., Roberts M.S. Physiologically based pharmacokinetics and pharmacodynamics of skin. Dermal Absorption and Toxicity Assessment 2008, 179-207. Informa Healthcare, New York. M.S. Roberts, K.A. Walters (Eds.).
142. Varvel J.R., Shafer S.L., Hwang S.S., Coen P.A., Stanski D.R. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989, 70:928-934.
143. Roberts M.S., Favretto W.A., Meyer A., Reckmann M., Wongseelashote T. Topical bioavailability of methyl salicylate. Aust. N. Z. J. Med. 1982, 12:303-305.
144. Nakashima E., Noonan P.K., Benet L.Z. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin. J. Pharmacokinet. Biopharm. 1987, 15:423-437.
145. Tang-Liu D.D., Matsumoto R.M., Usansky J.I. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin. Pharmacokinet. 1999, 37:273-287.
146. Sobue S., Sekiguchi K., Kikkawa H., Irie S. Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch. J. Clin. Pharmacol. 2005, 45:1391-1399.
147. Hotchkiss S.A.M. Dermal metabolism. Dermal Absorption and Toxicity Assessment 1998, 43-101. Marcel Dekker, New York, New York. M.S. Roberts, K.A. Walters (Eds.).
148. Dancik Y., Thorling C.A., Krishnan G., Roberts M.S. Cutaneous metabolism and active transport in transdermal drug delivery. Toxicology of the Skin 2010, 69-82. Taylor & Francis, Boca Raton. M.-R. N. (Ed.).
149. Wu Y.-T., Anissimov Y.G., Roberts M.S. Introduction to dermatokinetics. Dermatokinetics of Therapeutic Agents 2011, CRC Press Taylor & Francis, Boca Raton. N. Murthy (Ed.).
150. Seko N., Bando H., Lim C.W., Yamashita F., Hashida M. Theoretical analysis of the effect of cutaneous metabolism on skin permeation of parabens based on a two-layer skin diffusion/metabolism model. Biol. Pharm. Bull. 1999, 22:281-287.
151. Oliyai R., Stella V.J. Prodrugs of peptides and proteins for improved formulation and delivery. Annu. Rev. Pharmacol. Toxicol. 1993, 33:521-544.
152. Lefevre G., Sedek G., Huang H.L., Saltzman M., Rosenberg M., Kiese B., Fordham P. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol. 2007, 47:471-478.
153. Bodor N., Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev. 2000, 20:58-101.
154. Stinchcomb A.L., Swaan P.W., Ekabo O., Harris K.K., Browe J., Hammell D.C., Cooperman T.A., Pearsall M. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci. 2002, 91:2571-2578.
155. Beall H.D., Sloan K.B. Topical delivery of 5-fluorouracil (5-FU) by 1,3-bisalkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 2002, 231:43-49.
156. Doh H.J., Cho W.J., Yong C.S., Choi H.G., Kim J.S., Lee C.H., Kim D.D. Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery. J. Pharm. Sci. 2003, 92:1008-1017.
157. Sung K.C., Fang J.Y., Hu O.Y. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis. J. Control. Release 2000, 67:1-8.
158. Marks R. Pharmacokinetics and safety review of tazarotene. J. Am. Acad. Dermatol. 1998, 39:S134-S138.
159. Liu P., Higuchi W.I., Ghanem A.H., Good W.R. Transport of beta-estradiol in freshly excised human skin in vitro: diffusion and metabolism in each skin layer. Pharm. Res. 1994, 11:1777-1784.
160. Mavon A., Raufast V., Redoules D. Skin absorption and metabolism of a new vitamin E prodrug, delta-tocopherol-glucoside: in vitro evaluation in human skin models. J. Control. Release 2004, 100:221-231.
161. Bronaugh R.L., Maibach H.I. Percutaneous absorption of nitroaromatic compounds: in vivo and in vitro studies in the human and monkey. J. Invest. Dermatol. 1985, 84:180-183.
162. Bronaugh R.L., Franz T.J. Vehicle effects on percutaneous absorption: in vivo and in vitro comparisons with human skin. Br. J. Dermatol. 1986, 115:1-11.
163. Wester R.C., Maibach H.I., Melendres J., Sedik L., Knaak J., Wang R. In vivo and in vitro percutaneous absorption and skin evaporation of isofenphos in man. Fundam. Appl. Toxicol. 1992, 19:521-526.
164. Dick D., Ng K.M., Sauder D.N., Chu I. In vitro and in vivo percutaneous absorption of 14C-chloroform in humans. Hum. Exp. Toxicol. 1995, 14:260-265.
165. Dick I.P., Blain P.G., Williams F.M. The percutaneous absorption and skin distribution of lindane in man. II. In vitro studies. Hum. Exp. Toxicol. 1997, 16:652-657.
166. Griffin P., Mason H., Heywood K., Cocker J. Oral and dermal absorption of chlorpyrifos: a human volunteer study. Occup. Environ. Med. 1999, 56:10-13.
167. Griffin P., Payne M., Mason H., Freedlander E., Curran A.D., Cocker J. The in vitro percutaneous penetration of chlorpyrifos. Hum. Exp. Toxicol. 2000, 19:104-107.
168. Cnubben N.H., Elliott G.R., Hakkert B.C., Meuling W.J., van de Sandt J.J. Comparative in vitro-in vivo percutaneous penetration of the fungicide ortho-phenylphenol. Regul. Toxicol. Pharmacol. 2002, 35:198-208.
169. Mavon A., Miquel C., Lejeune O., Payre B., Moretto P. In vitro percutaneous absorption and in vivo stratum corneum distribution of an organic and a mineral sunscreen. Skin Pharmacol. Physiol. 2007, 20:10-20.
170. Davis A.F. Getting the dose right in dermatological therapy. Dermatologic, Cosmeceutic, and Cosmetic Development: Therapeutic and Novel Approaches 2008, 197-213. Informa Healthcare, New York. K.A. Walter, M.S. Roberts (Eds.).
171. Mertin D., Lippold B.C. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy. J. Pharm. Pharmacol. 1997, 49:866-872.
172. Wenkers B.P., Lippold B.C. Prediction of the efficacy of cutaneously applied nonsteroidal anti-inflammatory drugs from a lipophilic vehicle. Arzneimittelforschung 2000, 50:275-280.
173. Cordero J.A., Camacho M., Obach R., Domenech J., Vila L. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur. J. Pharm. Biopharm. 2001, 51:135-142.
174. Bando H., Mohri S., Yamashita F., Takakura Y., Hashida M. Effects of skin metabolism on percutaneous penetration of lipophilic drugs. J. Pharm. Sci. 1997, 86:759-761.
175. Beckett A.H., Gorrod J.W., Taylor D.C. Comparison of oral and percutaneous routes in man for the systemic administration of 'ephedrines'. J. Pharm. Pharmacol. 1972, 24:65P-70P. (Suppl.).